PPARD and metabolic dysfunction-associated steatohepatitis: Seladelpar (MBX‐8025), a selective PPAR‐δ agonist, has been shown to reverse NASH pathology in diabetic mouse models.92 Currently, a phase‐IIb randomized, placebo‐controlled study is testing three doses for 52 weeks in patients with liver‐biopsy NASH (NCT03551522).